AthleticsMD Clinical DeskSchedule an evaluation

Daily digest

What's trending, October 9, 2026

In the news

Patient-centered menopause care in the digital age

In a Healio commentary, five physicians summarise an expert panel discussion on individualized, culturally responsive menopause care. They cite a 2024 JAMA Health Forum study reporting that hormone therapy use fell from 26.9% of postmenopausal women in 1999 to 4.7% in 2020. They describe barriers including cultural stigma, limited clinician training, scarce representation and access gaps, and outline a framework for patient conversations.

Why it matters: Relevant to Maryland clinicians who counsel perimenopausal and menopausal patients, and to adults in the menopause transition preparing for conversations with their clinicians.

healio.com · October 9, 2026

Our summary →
In the news

The FDA Is Struggling To Police The Peptide Boom

In a commentary first published by Forbes and carried on Yahoo, health expert Sally Pipes argues the FDA's August warning letters to online sellers of unapproved peptides, including the experimental weight-loss drug retatrutide, are a start but miss overseas supply chains. She cites an import-record analysis finding at least eight retatrutide shipments from Chinese manufacturers in the first quarter of 2026, and proposes closer FDA-customs coordination.

Why it matters: Relevant to Maryland adults considering medical weight loss and to clinicians fielding patient questions about peptides sold online outside FDA-approved channels.

yahoo.com · October 9, 2026

Our summary →
In the news

Why do runners get so many injuries? And does strength training really make a difference?

In a piece by Hunter Bennett republished by Medical Xpress from The Conversation, the author explains that aerobic fitness can improve within two weeks while tendons need at least 12 weeks and bone remodeling can take months, which may explain overuse injuries in runners. A meta-analysis across sports found strength training cut injuries by more than 60%, but runner-specific evidence is mixed, with benefits seen mainly in supervised programs.

Why it matters: Relevant to Maryland adults who run or are starting to, and to sports medicine and rehabilitation clinicians who see runners with overuse injuries.

medicalxpress.com · October 9, 2026

Our summary →
In the news

Icotrokinra Retains Efficacy in Psoriasis Patients on GLP-1 Therapy

Clinical Advisor reports a post-hoc pooled analysis of phase 3 ICONIC data, presented at FC26, on oral icotrokinra for moderate to severe plaque psoriasis. Only 31 of 2187 patients were exposed to GLP-1 medications; their week-16 skin clearance, safety and drug levels appeared similar to non-users. Researchers noted small samples, reduced statistical power and missing GLP-1 dosing details limit interpretation.

Why it matters: Relevant to adults with moderate to severe plaque psoriasis who use GLP-1 medications, and the dermatology and weight-management clinicians who treat them.

clinicaladvisor.com · October 9, 2026

Our summary →
In the news

The GPS Framework For GLP-1s — How To Maintain Your Muscle

MindBodyGreen, in an expert-opinion piece syndicated on Yahoo, profiles endocrinologist Rocío Salas-Whalen, M.D., who says GLP-1 drugs do not directly cause muscle loss; lean mass falls with reduced eating. In her clinical view, about 10% or less of total weight lost as muscle is generally acceptable. Her proposed GPS framework pairs the medication with protein, roughly one gram per pound of ideal body weight, and at least two strength sessions per week.

Why it matters: Relevant to Maryland adults taking or considering GLP-1 medications, and to the obesity-medicine, nutrition and rehabilitation clinicians who counsel them during weight loss.

health.yahoo.com · October 9, 2026

Our summary →
In the news

Only one workout helped older adults lose fat and keep muscle

ScienceDaily reports on a University of the Sunshine Coast trial in Maturitas of 123 healthy older adults, average age 72, who did three supervised sessions of 45 minutes each week for six months. High- and moderate-intensity groups lost more fat than the low-intensity group, but only HIIT retained lean tissue. Researchers called the improvements relatively small, and the scans measured lean tissue, not strength.

Why it matters: Relevant to healthy older adults interested in how exercise intensity relates to body composition, and to the rehabilitation and preventive-care clinicians who work with them.

sciencedaily.com · October 9, 2026

Our summary →
In the news

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

News-Medical carries a company announcement from Oncopeptides on early data from its ongoing open-label INSULA study at Oslo University Hospital. In the first three patients with recurrent glioblastoma, given melflufen before scheduled surgery, resected tumor tissue contained active compound, which the company says indicates blood-brain barrier penetration. No major drug-related toxicity was reported so far; enrolment continues toward approximately 10 patients.

Why it matters: Relevant to clinicians who refer patients with recurrent glioblastoma for surgery and who follow early-stage research on delivering drugs into brain tumors.

news-medical.net · October 9, 2026

Our summary →

AthleticsMD Clinical Desk

Today's front page

The newest articles and the day's news on GLP-1 & weight loss, Metabolic health, Hormones and more.

Go to the front page →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.

Schedule an evaluation →